Is NRSN or NRXS more undervalued in 2026?

CirclFi compares NeuroSense Therapeutics Ltd. (NRSN) and Neuraxis, Inc. (NRXS) using 13 institutional-grade valuation models. NRSN has a Quality of Company score of 3.8/10 while NRXS scores 6.9/10.

Which is a better buy — NRSN or NRXS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NRSN and NRXS valuations compare?

NRSN at $0.86 and NRXS at $7.29 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NRSN vs NRXS Valuation Comparison 2026 — Intrinsic Value Analysis

NRSN

Biotechnology

NeuroSense Therapeutics Ltd.

Quality

3.8

out of 10

Value Trap

SAFE

Price

$0.86

Last close

Models

7/13

Active

NRXS

Biotechnology

Neuraxis, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$7.29

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	NRSN Fair Value	NRSN Upside	NRXS Fair Value	NRXS Upside
Bayesian DCF	Intrinsic	$0.24	-72.5%	$2.04	-72.0%
Earnings Power Value	Intrinsic	—	—	$1.57	-80.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.21	-75.4%	$0.86	-88.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NRSN vs NRXS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NRSN vs NRXS — Which Stock Is More Undervalued?

NRXS scores higher with a 6.9/10 quality rating vs NRSN's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NeuroSense Therapeutics Ltd. (NRSN) and Neuraxis, Inc. (NRXS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NRSN currently trades at $0.86 with a QOC of 3.8/10, while NRXS trades at $7.29 with a QOC of 6.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).